Compare Inovio Pharmaceuticals Inc (INO) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs MINISO Group Holding Ltd — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while MINISO Group Holding Ltd trades at $12.61 (market cap $3.87B). The key difference: MINISO Group Holding Ltd is far larger — about 43.4× Inovio Pharmaceuticals Inc's market cap, and MINISO Group Holding Ltd pays a 5.21% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | MNSO | |
|---|---|---|
Market Cap | $89.27M | $3.87B |
Sector | Health | Technology |
52-Week High | $2.87 | $26.63 |
52-Week Low | $1.05 | $11.30 |
Enterprise Value | $60.28M | $4.54B |
Dividend Yield | — | 5.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
MNSO trades at $12.79, up 0.31% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating EPS estimates with $0.591 versus $0.238 expected, and announced a HK$2 billion share repurchase program on June 29, 2026 (PRNewsWire). Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 13.02, indicating reasonable valuation.
The outlook is positive with projected revenue growth to $22.7 billion in 2026 and net profit doubling to $2.0 billion. However, risks include margin compression from rising expenses and mixed earnings history with two recent misses. Analyst consensus is 75% buy, but competitive pressures in retail remain a concern for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
